Therefore, this descriptive study aimed to examine the expression and activity of STAT3, STAT5, and STAT6 in PCa patients undergoing systemic therapies, including ADT, enzalutamide, abiraterone, and docetaxel. This evidence concerns the gene STAT6 and posterior cortical atrophy.